CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response
Summary
The tumor microenvironment (TME) poses a major barrier to effective immunotherapy, yet high-throughput perturbation-mapping approaches to dissect TME spatial complexity and its contextual immune modulators remain lacking. Here, we introduce CRISPR-laser-captured microdissection (LCM) integration mapping of the tumor-immune microenvironment (CLIM-TIME), a scalable platform that integrates CRISPR screening with LCM of metastatic tumors for transcriptomic, deconvolution, and immunofluorescenc
Content
# CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response
*Published: 2026 Mar 5*
The tumor microenvironment (TME) poses a major barrier to effective
immunotherapy, yet high-throughput perturbation-mapping approaches to dissect
TME spatial complexity and its contextual immune modulators remain lacking.
Here, we introduce CRISPR-laser-captured microdissection (LCM) integration
mapping of the tumor-immune microenvironment (CLIM-TIME), a scalable platform
that integrates CRISPR screening with LCM of metastatic tumors for
transcriptomic, deconvolution, and immunofluorescence analyses. CLIM-TIME
enables spatially resolved mapping of how tumor suppressor gene (TSG) loss
reshapes the TME and modulates immune responses. We identified seven distinct
TME subtypes, revealing that DNA repair and Polycomb repressive complex (PRC)
TSG loss is linked to immune-infiltrated TMEs sensitive to T cell therapy. In
contrast, knockouts of TSGs in the Hippo pathway promoted immune evasion and
therapy resistance by fostering myeloid-enriched but T cell-excluded TMEs with
elevated extracellular matrix (ECM). Targeting the ECM-crosslinking enzyme LOXL2
effectively remodeled the metastatic TME, enhancing T cell infiltration and
improving therapeutic efficacy in lung metastases across multiple cancers.
DOI: 10.1016/j.cell.2025.12.042